Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy

Table 3 Comparison of blood lipid levels between two groups of patients before and after treatment

Parameter	Time	CM group (n = 107)	CSCT group (n = 104)	t	P value
Tot-cholesterol (mg/dL)	Baseline	177.23 ± 34.56	180.25 ± 32.56	0.653	0.515
	6 months	171.45 ± 32.69	162.41 ± 31.79	2.037	0.043
HDL (mg/dL)	Baseline	45.26 ± 9.56	45.15 ± 9.89	0.079	0.937
	6 months	45.34 ± 8.66	47.69 ± 8.28	2.017	0.045
LDL (mg/dL)	Baseline	101.49 ± 35.26	105.21 ± 35.46	0.764	0.446
	6 months	94.86 ± 27.64	86.74 ± 27.12	2.154	0.032
Triglycerides (mg/dL)	Baseline	145.32 ± 35.64	142.89 ± 35.39	0.496	0.621
	6 months	135.21 ± 28.22	127.56 ± 25.26	2.072	0.040

HDL: High density lipoprotein; LDL: Low density lipoprotein; CM: Canagliflozin monotherapy; CSCT: Canagliflozin and semaglutide combination therapy.